FDA approves Pasatru as second treatment for fibrodysplasia ossificans progressiva
- nuaxia
- 5일 전
- 2분 분량
The approval provides adults with fibrodysplasia ossificans progressiva with a new treatment option designed to reduce abnormal bone formation and disease flare-ups in an ultra-rare genetic disorder. The US Food and Drug Administration (FDA) has approved Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP), making it the second approved treatment for the condition.
The approval offers an additional therapeutic option for adults with this progressive rare disease, although long-term treatment outcomes and paediatric use will continue to be evaluated.
Field | Content |
Alert Type | Drug Approval |
Drug Name | Pasatru (garetosmab-grts) |
Indication | Reduction of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). (U.S. Food and Drug Administration) |
Therapy Area(s) | Rare Diseases; Musculoskeletal Disorders; Genetics |
Geography | United States (FDA) |
What Happened | On 19 August 2026, the FDA approved Pasatru (garetosmab-grts) for adults with FOP. Pasatru is a fully human monoclonal antibody that blocks Activin A, a key driver of abnormal bone formation in the disease. The approval was supported by the Phase III OPTIMA trial, in which both evaluated doses significantly reduced the formation of new HO lesions and clinician-assessed flare-ups compared with placebo. Pasatru becomes the second FDA-approved treatment for FOP and the first approved therapy shown to reduce clinician-assessed flare-ups in a placebo-controlled trial. (U.S. Food and Drug Administration) |
Why It Matters | FOP is an ultra-rare inherited disorder in which muscle, tendons and ligaments progressively turn into bone, leading to severe disability and loss of mobility. Pasatru provides clinicians with an additional treatment option aimed at slowing new bone formation and reducing disease activity in adults, expanding therapeutic choice beyond the single previously approved medicine. (U.S. Food and Drug Administration) |
Supporting Context | FOP is caused by mutations in the ACVR1 gene that result in inappropriate activation of bone formation pathways. In the Phase III OPTIMA study, Pasatru reduced new HO lesions by around 90% or more compared with placebo over 56 weeks. (U.S. Food and Drug Administration) |
Key Takeaway | FDA approval gives adults with FOP a second approved treatment and introduces the first therapy demonstrated to reduce clinician-assessed disease flare-ups in a placebo-controlled study. (U.S. Food and Drug Administration) |
What to Watch | Commercial launch in the US, initiation of Regeneron's planned paediatric clinical programme, and regulatory submissions in additional markets. (Kelo) |
Primary Source | |
Relevant Date | 19 August 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
댓글